Curated news and analysis on clinical trials, drug approvals, and medical research.
Nuvation Bio reported updated Phase 2 data for safusidenib in IDH1-mutant glioma with a 52% ORR and 79% 36-month PFS rate. The company is expanding its clinical program with two new studies and expanding the SIGMA trial to a pivotal Phase 3, aiming to address broader patient populations.
A review highlights that stromal cell metabolism in the tumor microenvironment dominates immune suppression. Cancer-associated fibroblasts and adipocytes release metabolites that impair antitumor immunity while favoring tumor-promoting immune cells. Targeting these metabolic networks could restore immune function and boost immunotherapy efficacy.
Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
A study in JAMA Open finds that anti-kickback penalties paid by pharma companies amounted to just 2.2% of U.S. revenue from involved drugs. Pfizer recently disclosed $60,000 in lobbying on drug pricing and vaccine issues. Researchers say settlements act as a cost of doing business.
The Agency for Healthcare Research and Quality has cut off continuing funding for at least 73 projects, totaling over $102 million in committed funds. HHS says the move serves the federal government's best interest, but researchers warn that mid-stream grant freezes waste already-spent money and threaten the training of future health-care scientists.
Cornerstone Robotics will present at the 2nd Global Health Summit in August 2026, where its CEO will deliver a keynote on the evolution of surgical robotics. The company's Sentire surgical system has secured regulatory approvals in China, the EU, and Singapore, and is now used in hospitals across Asia-Pacific and Europe.
A 64-year-old Australian man was diagnosed with stage 3 breast cancer after his wife noticed bloodstains on his shirt, a case doctors say highlights that men can and do get the disease. Meanwhile, advances in precision medicine now allow breast cancer treatment to be tailored to each tumour’s biology and the patient’s overall health.
The FDA has upgraded a peanut butter recall to Class II after blue plastic fragments were found in a production filter. More than 22,000 single-serve packs from Ventura Foods were distributed to 40 states under various private-label brands. Consumers are advised to check labels and return or discard affected products.
Axpaxli (OTX-TKI) met its primary endpoint in the SOL-1 Phase 3 trial, demonstrating superiority over aflibercept in preserving visual acuity in wet AMD patients at week 36. A single injection of the intravitreal hydrogel led to higher rescue-free rates and better fluid control, supporting potential for reduced treatment burden. Ocular Therapeutix plans to submit a New Drug Application to the FDA.
A cross-sectional study shows that type 2 diabetes and body mass index independently worsen arterial stiffness, with BMI having a greater impact. No synergy was found between the two risk factors.
4D Molecular Therapeutics (Nasdaq: FDMT) granted a total of 229,700 restricted stock units to 20 new non-executive hires across three awards in 2026 under its Employment Inducement Award Plan. The grants occurred on February 10, April 14, and July 14, as part of Nasdaq-compliant inducement awards.
State Street's top five performing ETFs from June 16 to July 16, 2026, were all in the healthcare sector, with the SPDR S&P Pharmaceuticals ETF (XPH) leading at 11.69%. Other top performers included biotechnology, healthcare services, insurance, and healthcare equipment ETFs.
A securities class action lawsuit alleges REGENXBIO misled investors about the safety of its gene therapy RGX-111. Following an FDA clinical hold due to a patient tumor, the stock fell 17.8% in one day. Affected shareholders have until April 14, 2026 to seek lead plaintiff status.
High-resolution CT scans, virtual surgical planning, and 3D-printed custom guides are improving precision in pediatric orthopedic surgeries. The approach shortens operative times, reduces radiation exposure, and enhances limb alignment, as shown in a case of a severe tibial deformity. The technology is poised to become standard for complex pediatric procedures.
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
The global personalized medicine market is projected to grow from $789.39 billion in 2026 to $1.4 trillion by 2035, driven by genomic sequencing and companion diagnostics. North America leads with 46% of implementation, and AI-assisted interpretation is increasingly integrated.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
The FDA accepted Camurus' NDA resubmission for Oclaiz in acromegaly, setting a December 2026 PDUFA date. The filing follows a June 2026 Complete Response Letter related to third-party manufacturing, with no safety or efficacy issues. Oclaiz is a once-monthly subcutaneous octreotide already approved in the EU as Oczyesa.
New imaging reveals that most flu infections fail due to transcription errors, while host-targeted antivirals aim to bypass resistance by interfering with cellular machinery. The findings from Cell Systems point to new ways to predict viral threats and develop broad-spectrum drugs.
Laboratory monkey prices in China have surged to as much as 180,000 yuan, exceeding average wages, as booming drug research drives demand beyond limited supply. Researchers report that colonies are fully pre-booked, forcing some studies to halt. Supply-demand imbalance is forecast to persist, leading to further price increases.
